Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07371468 | A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) | PHASE1 | RECRUITING | 54 | — | — | Feb 10, 2026 | Mar 15, 2028 | Mar 17, 2026 | 3 | Japan |
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose Escalation of GSK5926371 | EXPERIMENTAL | - |
| Part 2: Dose Division of GSK5926371 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5926371 | BIOLOGICAL | GSK5926371 will be administered. |
Inclusion Criteria: * Part 1 will enroll adult participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). * Part 2 will enroll adult participants with SLE, RA, idiopathic inflammatory myopathies (IIM) or Sjogren's disease (SjD). * Participants must be 18 to 70 years of age i...